Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of Elafibranor 120 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function

NCT03844555 is registered in ClinicalTrials.gov with Genfit as lead sponsor.

NCT NCT03844555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03844555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of Elafibranor 120 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function
Lead sponsor
Genfit
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2019
Completion date
March 21, 2020
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney diseases, pharmacokinetics, renal impairment, renal insufficiency